Pamplona

• A Study to Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospha … Ended recruitment
  2023-504028-24-00 5 2023-09-22 Large B-Cell Lymphoma
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L … Ended recruitment
  2024-515047-31-00 5 2023-08-28 Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
• Master Protocol of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobilia … Ended recruitment
  2022-502317-29-00 4 2023-07-12 Advanced Hepatobiliary Cancer
• An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab … Ended recruitment
  2024-514016-26-00 4 2023-06-22 Multiple Myeloma
• A study to test trimodulin in adult hospitalized patients with severe pneumonia Ended recruitment
  2022-501352-28-00 5 2023-06-07 Severe community-acquired pneumonia (sCAP)
• Clinical study to investigate efficacy of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investiga … Ended recruitment
  2022-502065-23-00 4 2023-06-01 Refractory Metastatic Colorectal Cancer
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Ended recruitment
  2022-501463-40-01 5 2023-05-03 Locally Advanced or Metastatic Cholangiocarcinoma
• A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une … Ended recruitment
  2024-513460-26-00 5 2023-03-29 Refractory Chronic Cough, Including Unexplained Chronic Cough
• "Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Children with Partial-onset (Focal) Seizures " Ended recruitment
  2023-506841-52-00 5 2023-03-22 partial-onset (focal) seizures
• A Clinical Study to evaluate the long-term safety of Daratumumab in combination with standard bone marrow cancer treatment regiments Ended recruitment
  2022-500138-27-01 5 2023-02-28 Multiple Myeloma
• A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin … Ended recruitment
  2024-518486-10-00 4 2023-02-23 Non-Muscle Invasive Bladder Cancer
• Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS … Ended recruitment
  2023-508498-97-00 5 2023-02-03 Systemic Lupus Erythematosus
• A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o … Ended recruitment
  2023-504277-20-00 5 2023-01-30 Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorde
• A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended recruitment
  2022-501744-15-00 5 2023-01-23 Obesity, Overweight
• This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics … Ended recruitment
  2023-510061-10-00 3 2023-01-09 Clear cell renal cell carcinoma (ccRCC, first-, second- and third-line
• Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mut … Ended recruitment
  2024-511548-19-00 1 2022-12-13 Pancreatic Ductal Adenocarcinoma
• Study to evaluate the long-term safety of GT005 in participants having macular degeneration that led to geographic atrophy in their eyes and … Ended recruitment
  2024-510946-15-00 9 2022-12-08 Geographic atrophy (GA) secondary to age-related macular degeneration
• Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended recruitment
  2023-509825-38-00 5 2022-12-01 Metastatic Non–Small Cell Lung Cancer
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504741-32-00 4 2022-11-30 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit … Ended recruitment
  2023-504743-13-00 4 2022-11-30 Moderately to Severely Active Ulcerative Colitis
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refract … Ended recruitment
  2023-505212-38-00 3 2022-11-16 Relapsed/Refractory Multiple Myeloma
• Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Ended recruitment
  2023-508284-77-00 5 2022-11-16 Generalized Myasthenia Gravis with autoantibodies against acetylcholin
• SC versus IV isatuximab in combination with pomalidomide and dexamethasone in RRMM Ended recruitment
  2023-508869-32-00 5 2022-11-10 Cancer - Plasma cell myeloma recurrent

Showing 481–504 of 821 trials